Mirum Pharmaceuticals Stock Price, News & Analysis

Mirum Pharmaceuticals (NASDAQ:MIRM) reported strong Q2 2025 financial results, with total revenue of $128 million, driven by robust commercial performance. The company raised its 2025 revenue guidance to $490-510 million.

LIVMARLI net product sales reached $88.2 million, showing 87% growth year-over-year, while Bile Acid Medicines generated $39.6 million in sales, up 30% from Q2 2024. The company launched LIVMARLI single oral tablet dose in the U.S. in June.

Mirum maintains a strong financial position with $321.7 million in cash and investments. The company's pipeline is advancing with three important late-stage clinical milestones expected in 2026, including the VISTAS study in PSC, VANTAGE study in PBC, and LIVMARLI EXPAND Phase 3 study.

Mirum Pharmaceuticals (NASDAQ:MIRM) has scheduled its second quarter 2025 financial results announcement and conference call for August 6, 2025 at 4:30 p.m. ET. The company will discuss Q2 2025 financial performance and provide updates on recent corporate developments.

Investors can join via phone using U.S. toll-free number +1 833 470 1428 or international number +1 404 975 4839 with access code 448461. A webcast option is available through Mirum's website Events & Presentations section, with replay access for 30 days following the call.

Mirum Pharmaceuticals (NASDAQ:MIRM) announced inducement grants to two new employees under its 2020 Inducement Plan. The compensation package includes 14,460 non-qualified stock options at an exercise price of $53.01 per share and 7,220 restricted stock units (RSUs).

The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually, subject to continued employment.

Mirum Pharmaceuticals announced inducement awards granted to 10 new employees on June 10, 2025, approved by the Compensation Committee. The awards include 115,620 non-qualified stock options at an exercise price of $48.98 per share and 57,740 restricted stock units (RSUs). The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually. Both awards are contingent on continued employment and were granted under Mirum's 2020 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Mirum Pharmaceuticals (NASDAQ: MIRM) has appointed Doug Sheehy, JD as Chief Legal Officer. Sheehy brings nearly 20 years of experience in leading global legal and compliance operations for biopharmaceutical companies. His most recent role was CLO at Sonoma Biotherapeutics. Previously, he served as general counsel at Aimmune Therapeutics (2016-2020) until its Nestle Health Science acquisition, and as EVP, CAO, and general counsel at Codexis (2007-2016). Sheehy holds an A.B. in History from Dartmouth College and a J.D. from American University. CEO Chris Peetz highlighted that Sheehy's extensive global legal experience will strengthen Mirum's capabilities as they expand their commercial business and advance their rare disease pipeline.

Mirum Pharmaceuticals (Nasdaq: MIRM), a biopharmaceutical company specializing in rare and orphan diseases, has announced its participation in two upcoming investor conferences in May 2025. The company will attend the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20th and deliver a company presentation at the RBC Capital Markets Global Healthcare Conference on May 21st at 9:00 AM ET. Interested parties can access webcast links and additional information through the Investors and Media section of Mirum's corporate website.

Mirum Pharmaceuticals (NASDAQ: MIRM) announced inducement awards granted to eight new employees on May 9, 2025. The awards, approved by the Compensation Committee, include:

- Stock options to purchase 53,230 shares at $44.27 per share (closing price on May 9), vesting over 4 years with 25% vesting after one year and remaining monthly over 36 months

- 26,585 restricted stock units (RSUs) vesting over 3 years with 33% vesting annually

The grants were made under Mirum's 2020 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), subject to continued employment.

Mirum Pharmaceuticals presented promising 28-week data from its Phase 2b VANTAGE study evaluating volixibat for cholestatic pruritus in primary biliary cholangitis (PBC) patients at EASL. The study showed statistically significant improvements in pruritus (itching) and numeric improvements in fatigue, the two most burdensome PBC symptoms.

Key findings include:

• 70% of volixibat-treated patients achieved ≥50% reduction in serum bile acids
• Statistically significant 3.78-point reduction in ItchRO from baseline in the combined dose group
• Both 20mg and 80mg BID doses showed similar efficacy
• Improvements in quality of life measures and reductions in IL-31 inflammatory biomarker

The most common adverse event was mild to moderate diarrhea (77%). Based on similar efficacy and safety results, the 20mg BID dose was selected for the confirmatory portion of the VANTAGE study.

Mirum Pharmaceuticals (MIRM) reported strong Q1 2025 financial results with total revenue of $111.6 million, a significant increase from $69.2 million in Q1 2024. The company raised its 2025 revenue guidance to $435-450 million. LIVMARLI net product sales reached $73.2 million (71% YoY growth), while Bile Acid Medicines contributed $38.4 million (47% YoY growth). Key achievements include FDA approval of LIVMARLI's oral tablet formulation, Japanese approval for ALGS and PFIC, and CTEXLI approval in the US. The VISTAS study for volixibat in PSC is expected to complete enrollment in Q3 2025. Mirum maintains a strong financial position with $298.6 million in cash and investments as of March 31, 2025.